NextCure (NASDAQ:NXTC) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of NextCure (NASDAQ:NXTC) in a research report released on Friday morning, Benzinga reports. They currently have a $4.00 price target on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $8.00 target price on shares of NextCure in a report on Friday.

NextCure Stock Performance

NextCure stock opened at $1.65 on Friday. The business has a 50 day simple moving average of $1.72 and a 200 day simple moving average of $1.40. NextCure has a one year low of $0.98 and a one year high of $2.57.

NextCure (NASDAQ:NXTC) last announced its earnings results on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.02. As a group, sell-side analysts anticipate that NextCure will post -1.65 EPS for the current fiscal year.

Institutional Investors Weigh In On NextCure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cable Car Capital LLC bought a new stake in shares of NextCure during the fourth quarter valued at approximately $702,000. Assenagon Asset Management S.A. bought a new position in NextCure in the 1st quarter valued at $952,000. Acuitas Investments LLC increased its stake in shares of NextCure by 30.0% in the 4th quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock valued at $425,000 after buying an additional 85,982 shares during the period. Finally, Marquette Asset Management LLC bought a new stake in shares of NextCure during the fourth quarter worth $66,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.